Plain-English translation of NCT06971211 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination of three treatments for men with metastatic castration-resistant prostate cancer (advanced prostate cancer that has spread and stopped responding to hormone therapy). The combination includes fluzoparib, abiraterone acetate, and radiation therapy. Researchers want to see if using these treatments together can slow or stop the cancer better than using them alone.
Men whose prostate cancer stops responding to standard hormone therapy have few good treatment options. This trial exists to test whether adding radiation and a newer medication called fluzoparib to existing hormone treatment might help more patients control their cancer longer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will first enter an induction phase where you receive radiation therapy (called IMRT) combined with two oral medications that you take by mouth daily, plus a steroid. Each treatment cycle lasts 28 days. After the induction phase, you move to a maintenance phase where you continue taking the two oral medications and steroid without radiation. You will continue treatment until your cancer starts progressing again or you and your doctor decide the treatment is no longer helping. Throughout the study, you will have regular visits to check your blood counts, PSA levels (a cancer marker), and overall health, with follow-up continuing even after treatment stops.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
China